Last 7 days
-3.7%
Last 30 days
21.1%
Last 90 days
10.1%
Trailing 12 Months
121.0%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
TMO | 230.7B | 43.8B | -5.06% | -2.55% | 33.15 | 5.14 | 6.53% | -9.94% |
IQV | 36.6B | 14.5B | 3.00% | -2.89% | 34.72 | 2.53 | 3.29% | -2.22% |
INCY | 14.0B | 3.4B | -14.52% | -17.83% | 43.23 | 4.13 | 13.67% | -65.23% |
CRL | 10.0B | 4.1B | 3.89% | -12.79% | 20.1 | 2.44 | 12.73% | 17.48% |
MID-CAP | ||||||||
MEDP | 6.2B | 1.6B | -2.93% | 52.95% | 24.09 | 3.96 | 28.83% | 28.57% |
SYNH | 4.3B | 5.4B | 9.59% | -41.20% | 28.88 | 0.79 | 1.37% | -38.84% |
ARWR | 3.6B | 272.8M | -0.03% | -1.18% | -23.88 | 13.15 | 3.56% | -34.35% |
NEO | 2.2B | 529.8M | 21.13% | 120.99% | -17.59 | 4.17 | 9.02% | -252.50% |
SMALL-CAP | ||||||||
AVXL | 718.9M | - | 15.32% | -1.54% | -13.63 | 291.16 | -34.21% | -22.02% |
PGEN | 306.6M | 23.2M | 6.19% | -3.23% | 12.35 | 13.19 | -45.75% | 126.39% |
SRNE | 170.9M | - | -71.28% | -88.95% | -0.25 | 2.64 | 22.40% | -42.61% |
CDXC | 106.8M | 77.3M | 6.72% | -15.88% | -9.98 | 1.38 | 10.46% | 61.07% |
PSNL | 90.7M | 68.7M | -11.82% | -52.10% | -0.8 | 1.32 | -13.98% | -40.40% |
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Revenue | 3.9% | 529,779,000 | 509,728,000 | 496,755,000 | 489,313,000 | 485,965,000 |
Gross Profit | 8.8% | 204,478,000 | 187,896,000 | 176,328,000 | 174,674,000 | 183,718,000 |
Operating Expenses | -0.1% | 345,146,000 | 345,519,000 | 349,135,000 | 347,684,000 | 339,393,000 |
S&GA Expenses | -0.1% | 67,281,000 | 67,321,000 | 66,096,000 | 64,991,000 | 65,144,000 |
R&D Expenses | -1.0% | 30,008,000 | 30,326,000 | 32,164,000 | 32,261,000 | 27,130,000 |
EBITDA | 12.3% | -122,464,000 | -139,670,000 | -122,854,000 | -9,986,000 | - |
EBITDA Margin | 14.6% | -0.24 | -0.28 | -0.25 | -0.02 | - |
Earnings Before Taxes | 12.2% | -139,901,000 | -159,342,000 | -178,022,000 | -161,568,000 | -47,099,000 |
EBT Margin | 12.8% | -0.31 | -0.36 | -0.33 | -0.10 | - |
Interest Expenses | -63.0% | 1,506,000 | 4,073,000 | 5,230,000 | 5,206,000 | - |
Net Income | 12.9% | -125,637,000 | -144,250,000 | -163,322,000 | -146,818,000 | -35,642,000 |
Net Income Margin | 13.9% | -0.28 | -0.33 | -0.30 | -0.07 | - |
Free Cahsflow | 19.6% | -96,884,000 | -120,428,000 | -119,056,000 | -114,503,000 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Assets | -1.8% | 1,709 | 1,740 | 1,756 | 1,792 | 1,830 |
Current Assets | -3.4% | 585 | 605 | 603 | 622 | 651 |
Cash Equivalents | 4.7% | 276 | 263 | 266 | 284 | 306 |
Inventory | 0.6% | 24.00 | 24.00 | 24.00 | 22.00 | 24.00 |
Net PPE | 0.3% | 103 | 102 | 107 | 111 | 109 |
Goodwill | 0% | 523 | 523 | 523 | 527 | 527 |
Liabilities | -1.0% | 735 | 742 | 743 | 749 | 755 |
Current Liabilities | -3.7% | 87.00 | 90.00 | 85.00 | 83.00 | 82.00 |
Shareholder's Equity | -2.4% | 974 | 998 | 1,013 | 1,044 | 1,075 |
Retained Earnings | -19.4% | -189 | -159 | -136 | -99.55 | -64.24 |
Additional Paid-In Capital | 0.5% | 1,167 | 1,161 | 1,154 | 1,147 | 1,142 |
Accumulated Depreciation | 5.3% | 139 | 132 | 125 | 123 | 116 |
Shares Outstanding | 2.5% | 127 | 124 | 127 | 126 | 125 |
Cashflow (Last 12 Months) | (In Thousands) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Cashflow From Operations | 24.8% | -49,645 | -65,993 | -82,084 | -73,579 | -57,973 |
Share Based Compensation | -29.8% | 17,327 | 24,672 | 30,071 | 31,028 | 31,908 |
Cashflow From Investing | 2261.1% | 12,207 | 517 | -8,003 | -18,491 | -465,627 |
Cashflow From Financing | -39.5% | 7,151 | 11,829 | 12,487 | 2,808 | 206,407 |
99.2%
66.2%
30%
Y-axis is the maximum loss one would have experienced if Neogenomics was unfortunately bought at previous high price.
17.0%
10.5%
8.4%
-14.9%
FIve years rolling returns for Neogenomics.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-05-23 | ROYCE & ASSOCIATES LP | reduced | -5.65 | 3,431,510 | 7,844,080 | 0.08% |
2023-05-22 | AMERIPRISE FINANCIAL INC | reduced | -21.47 | 5,483,450 | 16,911,400 | 0.01% |
2023-05-18 | NEW YORK STATE COMMON RETIREMENT FUND | unchanged | - | 222,000 | 1,935,000 | -% |
2023-05-18 | JPMORGAN CHASE & CO | reduced | -20.38 | 6,958,000 | 20,865,000 | -% |
2023-05-18 | NEW YORK STATE COMMON RETIREMENT FUND | added | 112 | 3,369,000 | 4,488,000 | 0.01% |
2023-05-18 | NEW YORK STATE COMMON RETIREMENT FUND | added | 12.83 | 704,000 | 3,526,000 | -% |
2023-05-17 | Sunbelt Securities, Inc. | reduced | -91.72 | -224,932 | 42,141 | 0.01% |
2023-05-17 | Advisory Services Network, LLC | unchanged | - | 32,843 | 69,988 | -% |
2023-05-17 | Thrivent Financial for Lutherans | reduced | -3.39 | 982,000 | 2,179,000 | -% |
2023-05-16 | Rockefeller Capital Management L.P. | added | 0.47 | 447,000 | 607,000 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 10, 2023 | artisan partners limited partnership | 0.0% | 10 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 10.83% | 13,674,745 | SC 13G/A | |
Feb 09, 2023 | brown advisory inc | 5% | 6,337,008 | SC 13G | |
Feb 06, 2023 | wellington management group llp | 0.00% | 0 | SC 13G/A | |
Jan 23, 2023 | blackrock inc. | 17.4% | 21,932,623 | SC 13G/A | |
Feb 04, 2022 | wellington management group llp | 8.99% | 11,069,283 | SC 13G | |
Feb 04, 2022 | artisan partners limited partnership | 6.3% | 7,732,355 | SC 13G | |
Jan 27, 2022 | blackrock inc. | 15.7% | 19,328,254 | SC 13G/A | |
Jan 26, 2022 | blackrock inc. | 15.7% | 19,328,254 | SC 13G | |
Feb 10, 2021 | vanguard group inc | 10.06% | 11,167,578 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
May 24, 2023 | 3 | Insider Trading | |
May 24, 2023 | 4 | Insider Trading | |
May 17, 2023 | 8-K | Current Report | |
May 15, 2023 | 4 | Insider Trading | |
May 15, 2023 | 4 | Insider Trading | |
May 15, 2023 | 4 | Insider Trading | |
May 15, 2023 | 4 | Insider Trading | |
May 15, 2023 | 4 | Insider Trading | |
May 15, 2023 | 4 | Insider Trading | |
May 09, 2023 | 10-Q | Quarterly Report |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-05-22 | TETRAULT LYNN A. | acquired | 17,481 | 11.6 | 1,507 | - |
2023-05-01 | Olivo Alicia C | sold (taxes) | - | - | -662 | general counsel |
2023-04-01 | Kulkarni Shashikant | sold (taxes) | - | - | -3,759 | chief scientific officer |
2023-03-02 | Dieter Cynthia J | sold (taxes) | - | - | -117 | chief accounting officer |
2023-03-01 | Dieter Cynthia J | sold (taxes) | - | - | -880 | chief accounting officer |
2023-01-01 | Harris Melody | acquired | - | - | 108,225 | president, enterprise ops |
2022-12-31 | Sikri Vishal | acquired | 1,584 | 7.04 | 225 | president, pharma services |
2022-12-31 | Dieter Cynthia J | sold (taxes) | - | - | -959 | chief accounting officer |
2022-12-05 | Sherman Jeffrey Scott | acquired | - | - | 133,809 | chief financial officer |
2022-12-01 | Stone Warren | acquired | - | - | 89,206 | president, clinical services |
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2023 | Mar. 31, 2022 | |
Total net revenue | $ 137,220 | $ 117,169 |
COST OF REVENUE | 82,406 | 78,937 |
GROSS PROFIT | 54,814 | 38,232 |
Operating expenses: | ||
General and administrative | 61,549 | 66,248 |
Research and development | 7,395 | 7,713 |
Sales and marketing | 16,259 | 16,299 |
Restructuring charges | 4,684 | 0 |
Total operating expenses | 89,887 | 90,260 |
LOSS FROM OPERATIONS | (35,073) | (52,028) |
Interest (income) expense, net | (1,467) | 1,301 |
Other expense (income), net | 114 | (168) |
Loss before taxes | (33,720) | (53,161) |
Income tax benefit | (2,925) | (3,753) |
NET LOSS | $ (30,795) | $ (49,408) |
NET LOSS PER SHARE | ||
Basic (in dollars per share) | $ (0.25) | $ (0.40) |
Diluted (in dollars per share) | $ (0.25) | $ (0.40) |
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING | ||
Basic (in shares) | 125,026 | 123,630 |
Diluted (in shares) | 125,026 | 123,630 |
Clinical Services | ||
Total net revenue | $ 114,869 | $ 98,791 |
COST OF REVENUE | 67,292 | 65,267 |
GROSS PROFIT | 47,577 | 33,524 |
Pharma Services | ||
Total net revenue | 22,351 | 18,378 |
COST OF REVENUE | 15,114 | 13,670 |
GROSS PROFIT | $ 7,237 | $ 4,708 |
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets | ||
Cash and cash equivalents | $ 275,609 | $ 263,180 |
Marketable securities, at fair value | 142,306 | 174,809 |
Accounts receivable, net | 118,842 | 119,711 |
Inventories | 24,432 | 24,277 |
Prepaid assets | 16,185 | 15,237 |
Other current assets | 7,622 | 8,077 |
Total current assets | 584,996 | 605,291 |
Property and equipment (net of accumulated depreciation of $138,863 and $131,930, respectively) | 102,845 | 102,499 |
Operating lease right-of-use assets | 93,784 | 96,109 |
Intangible assets, net | 399,477 | 408,260 |
Goodwill | 522,766 | 522,766 |
Other assets | 5,306 | 5,109 |
Total non-current assets | 1,124,178 | 1,134,743 |
Total assets | 1,709,174 | 1,740,034 |
Current liabilities | ||
Accounts payable | 22,712 | 20,510 |
Accrued compensation | 32,891 | 40,141 |
Accrued expenses and other liabilities | 17,964 | 15,070 |
Current portion of equipment financing obligations | 38 | 70 |
Current portion of operating lease liabilities | 6,934 | 6,584 |
Pharma contract liabilities | 6,067 | 7,557 |
Total current liabilities | 86,606 | 89,932 |
Long-term liabilities | ||
Convertible senior notes, net | 536,037 | 535,322 |
Operating lease liabilities | 67,319 | 68,952 |
Deferred income tax liabilities, net | 31,715 | 34,750 |
Other long-term liabilities | 13,035 | 13,055 |
Total long-term liabilities | 648,106 | 652,079 |
Total liabilities | 734,712 | 742,011 |
Commitments and contingencies (Note 11) | ||
Stockholders’ equity | ||
Common stock, $0.001 par value, (250,000,000 shares authorized; 127,200,491 and 126,913,992 shares issued and outstanding, respectively) | 127 | 127 |
Additional paid-in capital | 1,167,051 | 1,160,882 |
Accumulated other comprehensive loss | (2,834) | (3,899) |
Accumulated deficit | (189,882) | (159,087) |
Total stockholders’ equity | 974,462 | 998,023 |
Total liabilities and stockholders’ equity | $ 1,709,174 | $ 1,740,034 |